Attached files
file | filename |
---|---|
10-K/A - AMENDMENT NO.1 TO FORM 10-K - Nuo Therapeutics, Inc. | v324789_10ka.htm |
EX-31.2 - EXHIBIT 31.2 - Nuo Therapeutics, Inc. | v324789_ex31x2.htm |
EX-31.1 - EXHIBIT 31.1 - Nuo Therapeutics, Inc. | v324789_ex31x1.htm |
EX-23.2 - EXHIBIT 23.2 - Nuo Therapeutics, Inc. | v324789_ex23x2.htm |
EX-23.1 - EXHIBIT 23.1 - Nuo Therapeutics, Inc. | v324789_ex23x1.htm |
EX-32.1 - EXHIBIT 32.1 - Nuo Therapeutics, Inc. | v324789_ex32x1.htm |
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. §1350
Pursuant to 18 U.S.C. §1350 and in connection with the Annual Report on Form 10-K/A (Amendment No. 1) of Cytomedix, Inc. (the Company) for the fiscal year ended December 31, 2011 (the Report), I, Andrew S. Maslan, Chief Financial Officer of the Company, hereby certify that to the best of my knowledge and belief:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. |
Date: October 16, 2012
/s/ Andrew S. Maslan Andrew S. Maslan Chief Financial Officer |
A signed original of this written statement has been provided to Cytomedix, Inc. and will be retained by Cytomedix, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.